A Procalcitonin-based Algorithm in Adhesion-related Small Bowel Obstruction
Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · Apr 4, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help doctors decide how to treat patients with a condition called adhesion-related small bowel obstruction (ASBO). ASBO happens when the intestines get blocked due to scar tissue from previous surgeries. Doctors can choose to treat this condition either without surgery or with an operation, but it can be hard to know the best choice. In this trial, researchers are looking at a method that uses a blood test for a substance called procalcitonin to guide treatment decisions.
To be part of this trial, participants need to be adults aged 65 to 74 who have uncomplicated acute ASBO and can give consent. They should also be covered by national health insurance. Those who have had recent abdominal surgery, certain types of cancer, or other specific health conditions will not be eligible. If someone joins the trial, they will undergo tests and evaluations to see how well the procalcitonin-based approach works in managing their condition. This research aims to improve treatment options and outcomes for patients facing this common digestive emergency.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Uncomplicated acute adhesion-related small bowel obstruction (ASBO)
- • Adults
- • Patients able to express consent
- • Signed written informed consent form
- • Covered by national health insurance
- Exclusion Criteria:
- * Disease-related criteria:
- • Large bowel obstruction
- • No previous abdominal surgery
- • Signs of peritonitis or strangulation requiring emergency surgery)
- • Obstruction within 4 weeks following previous surgery
- • Ongoing or history of bowel cancer
- • Ongoing or in history of inflammatory bowel disease
- • History of abdominal radiotherapy
- • Active infection
- • Contraindication to contrast-enhanced CT scan
- • Minors
- • Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision)
- • Pregnancy or breastfeeding
About Centre Hospitalier Universitaire, Amiens
The Centre Hospitalier Universitaire (CHU) Amiens is a leading academic medical center in France dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on multidisciplinary collaboration, CHU Amiens integrates patient care, education, and research to enhance treatment outcomes and improve patient quality of life. The institution is committed to ethical standards and regulatory compliance in its clinical research endeavors, aiming to contribute significantly to the medical community and the development of new therapeutic approaches. By fostering partnerships with various stakeholders, CHU Amiens strives to translate scientific discoveries into practical applications that benefit patients and healthcare systems alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amiens, , France
Patients applied
Trial Officials
Jean-Marc Regimbeau, Pr
Principal Investigator
CHU Amiens
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials